DEFINITY® News and Updates

Read More

Efficacy

DEFINITY® Improves Cardiac Diagnosis and Patient Management1

DEFINITY® has been shown to alter patient management decisions, leading to significant changes in medications, procedures, or both1

DEFINITY® reduces the number of diagnostic procedures conducted, decreases length of stay, and lowers the per-patient expense1

>95% of transthoracic echoes should be diagnostic with DEFINITY®.

With DEFINITY®, >95% of transthoracic echoes should be diagnostic2


90% of suboptimal echoes converted to adequate studies.

of suboptimal echoes converted to adequate studies1

36% change in patient management.

change in patient management1

28% reduction in mortality in the criticallill.

reduction in mortality in the critically ill3

24% decreased risk of mortality in hospitalized patients.

decreased risk of mortality in hospitalized patients4

10% shorter intensive care unit length of stay.

shorter intensive care unit length of stay5

5x reduction in unjustified, repeat transthoracic echoes.

reduction in unjustified, repeat transthoracic echoes6

Apical thrombus

Unenhanced

DEFINITY®


Enhanced Echocardiography: It's What You Don't See That Matters


Ben Lin, MD, Theresa Green, RDCS, and Sean McMahon, MD, present the Lantheus 2019 ASE Science & Technology Theater Program.


How DEFINITY® Works

DEFINITY® microbubbles are composed of octafluoropropane gas encapsulated by a synthetic phospholipid shell.7

The microbubbles effectively traverse the pulmonary vasculature to produce high-quality, consistent, and reliable images of the left ventricle.7-10

The DEFINITY® microbubble diameter of 1.1 to 3.3 microns is smaller than normal red blood cells.7,11

DEFINITY® Delivers High-Quality Images

DEFINITY® is the only ultrasound enhancing agent with mechanical activation.7,12,13 DEFINITY® is activated in VIALMIX® or VIALMIX® RFID, which contributes to consistent image quality.7,9

VIALMIX® activation device.
VIALMIX® RFID activation device.

References:

  1. Kurt M, Shaikh KA, Peterson L, et al. Impact of contrast echocardiography on evaluation of ventricular function and clinical management in a large prospective cohort. J Am Coll Cardiol. 2009;53(9):802-810.

  2. Picard MH, Adams D, Bierig SM, et al. American society of echocardiography: recommendations for quality echocardiography laboratory operations. J Am Soc Echocardiogr. 2011;24(1):1-10.

  3. Main ML, Hibberd MG, Ryan A, Lowe TJ, Miller P, Bhat G. Acute mortality in critically ill patients undergoing echocardiography with or without an ultrasound contrast agent. JACC Cardiovasc Imaging. 2014;7(1):40-48.

  4. Main ML, Ryan AC, Davis TE, Albano MP, Kusnetzky LL, Hibberd M. Acute mortality in hospitalized patients undergoing echocardiography with and without an ultrasound contrast agent (multicenter registry results in 4,300,966 consecutive patients). Am J Cardiol. 2008;102(12):1742-1746.

  5. Main ML, Fu JW, Gundrum J, LaPointe NA, Gillam LD, Mulvagh SL. Impact of contrast echocardiography on outcomes in critically ill patients. Am J Cardiol. 2021;150:117-122. doi:10.1016/j.amjcard.2021.03.039

  6. Lee KC, Liu S, Callahan P, et al. Routine use of contrast on admission transthoracic echocardiography for heart failure reduces the rate of repeat echocardiography during index admission. J Am Soc Echocardiogr. 2021;34(12):1253-1261.e4. doi:10.1016/j.echo.2021.07.008

  7. DEFINITY® [package insert]. N. Billerica, MA: Lantheus Medical Imaging, Inc.

  8. Kitzman DW, Goldman ME, Gillam LD, Cohen JL, Aurigemma GP, Gottdiener JS. Efficacy and safety of the novel ultrasound contrast agent perflutren (definity) in patients with suboptimal baseline left ventricular echocardiographic images. Am J Cardiol. 2000;86(6):669-674.

  9. Sboros V, Moran CM, Pye SD, McDicken WN. Contrast agent stability: a continuous B-mode imaging approach. Ultrasound Med Biol. 2001;27(10):1367-1377.

  10. Sonne C, Xie F, Lof J, et al. Differences in definity and optison microbubble destruction rates at a similar mechanical index with different real-time perfusion systems. J Am Soc Echocardiogr. 2003;16(11):1178-1185.

  11. Mayer S. Grayburn PA. Myocardial contrast agents: recent advances and future directions. Prog Cardiovasc Dis. 2001;44(1):33-44.

  12. Optison™ [package insert]. Marlborough, MA: GE Healthcare Inc.

  13. Lumason® [package insert]. Monroe Township, NJ: Bracco Diagnostics Inc.

INDICATIONS

DEFINITY® is indicated, after activation, for use in adult and pediatric patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.

IMPORTANT SAFETY INFORMATION

WARNING: SERIOUS CARDIOPULMONARY REACTIONS

Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following perflutren-containing microsphere administration. Most serious reactions occur within 30 minutes of administration.

  • Assess all patients for the presence of any condition that precludes DEFINITY® administration [see Contraindications (4)].
  • Always have resuscitation equipment and trained personnel readily available [see Warnings and Precautions (5.1)].